880 research outputs found
ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΈΠ½ΡΠ΅ΡΡΡΠΈΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π»Π΅Π³ΠΊΠΈΡ ΠΏΡΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ
Scleroderma systemitica (SDS) is an autoimmune connective tissue disease characterized by excessive fibrosis of the skin and viscera. SDS is prone to be chronic and progressive, is accompanied by the deterioration in quality of life and working ability and has an unfavorable prognosis. Interstitial lung disease (ILD) is one of the most common causes of death due to SDS.The lecture deals with the clinical and laboratory instrumental features of ILD in SDS. SDS-associated ILD occurs in 65β80% of patients and is highly diverse in the degree of severity and the tendency to progression. In the majority of patients, the fibrous process in the lung occurs in the early years of the disease, is limited and progresses slowly. Severe lung damage with rapid progression develops only in 10β15% of cases. Evaluation of lung damage in SDS includes pulmonary function tests, lung diffusing capacity determination, Doppler echocardiography analysis, multispiral computed tomography (MSCT) of the chest, bronchoalveolar lavage, lung biopsy with morphological examination of its specimens, as well as right heart catheterization. The best technique for detecting ILD is MSCT, as chest radiography has a low sensitivity in the early stages of the disease. IPL is treated in accordance with the 2017 ACR/EULAR guidelines; the leading role is played by immunosuppressive drugs, such as cyclophosphamide and mycophenolate mofetil. Antifibrotic drugs (pirfenidone, nintedanib) are being tested now .Β Π‘ΠΈΡΡΠ΅ΠΌΠ½Π°Ρ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΡ (Π‘Π‘Π) β Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½Π½ΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ, ΠΊΠΎΡΠΎΡΠΎΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΠ΅ΡΡΡ ΠΈΠ·Π±ΡΡΠΎΡΠ½ΡΠΌ ΡΠΈΠ±ΡΠΎΠ·ΠΎΠΌ ΠΊΠΎΠΆΠΈ ΠΈ Π²Π½ΡΡΡΠ΅Π½Π½ΠΈΡ
ΠΎΡΠ³Π°Π½ΠΎΠ². Π‘Π‘Π ΡΠΊΠ»ΠΎΠ½Π½Π° ΠΊ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌΡ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΈ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ, ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°Π΅ΡΡΡ ΡΡ
ΡΠ΄ΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ, ΡΡΡΠ΄ΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ ΠΈ ΠΈΠΌΠ΅Π΅Ρ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΉ ΠΏΡΠΎΠ³Π½ΠΎΠ·.ΠΠ½ΡΠ΅ΡΡΡΠΈΡΠΈΠ°Π»ΡΠ½ΠΎΠ΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ Π»Π΅Π³ΠΊΠΈΡ
(ΠΠΠ) β ΠΎΠ΄Π½Π° ΠΈΠ· ΡΠ°ΠΌΡΡ
ΡΠ°ΡΡΡΡ
ΠΏΡΠΈΡΠΈΠ½ ΡΠΌΠ΅ΡΡΠΈ, ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½Π½ΠΎΠΉ Π‘Π‘Π. Π Π»Π΅ΠΊΡΠΈΠΈ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎ-ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΠΠ ΠΏΡΠΈ Π‘Π‘Π. ΠΠΠ, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ Ρ Π‘Π‘Π, Π²ΡΡΡΠ΅ΡΠ°Π΅ΡΡΡ Ρ 65β80% Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΈ ΠΎΡΠ»ΠΈΡΠ°Π΅ΡΡΡ Π±ΠΎΠ»ΡΡΠΈΠΌ ΡΠ°Π·Π½ΠΎΠΎΠ±ΡΠ°Π·ΠΈΠ΅ΠΌ ΠΏΠΎ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ ΠΈ ΡΠΊΠ»ΠΎΠ½Π½ΠΎΡΡΠΈ ΠΊ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ. Π£ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠΈΠ±ΡΠΎΠ·ΠΈΡΡΡΡΠΈΠΉ ΠΏΡΠΎΡΠ΅ΡΡ Π² Π»Π΅Π³ΠΊΠΈΡ
Π²ΠΎΠ·Π½ΠΈΠΊΠ°Π΅Ρ Π² ΠΏΠ΅ΡΠ²ΡΠ΅ Π³ΠΎΠ΄Ρ Π±ΠΎΠ»Π΅Π·Π½ΠΈ, Π½ΠΎΡΠΈΡ ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½Π½ΡΠΉ Ρ
Π°ΡΠ°ΠΊΡΠ΅Ρ ΠΈ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΡΠ΅Ρ ΠΌΠ΅Π΄Π»Π΅Π½Π½ΠΎ. Π’ΡΠΆΠ΅Π»ΠΎΠ΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ Π»Π΅Π³ΠΊΠΈΡ
Ρ Π±ΡΡΡΡΡΠΌ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΡΠ°Π·Π²ΠΈΠ²Π°Π΅ΡΡΡ ΡΠΎΠ»ΡΠΊΠΎ Π² 10β15% Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΉ.ΠΠ»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π»Π΅Π³ΠΊΠΈΡ
ΠΏΡΠΈ Π‘Π‘Π ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡΡ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ Π»Π΅Π³ΠΎΡΠ½ΡΠ΅ ΡΠ΅ΡΡΡ, ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π΄ΠΈΡΡΡΠ·ΠΈΠΎΠ½Π½ΠΎΠΉ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ Π»Π΅Π³ΠΊΠΈΡ
, ΡΡ
ΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΠ³ΡΠ°ΡΠΈΡ Ρ Π΄ΠΎΠΏΠ»Π΅ΡΠΎΠ²ΡΠΊΠΈΠΌ Π°Π½Π°Π»ΠΈΠ·ΠΎΠΌ, ΠΌΡΠ»ΡΡΠΈΡΠΏΠΈΡΠ°Π»ΡΠ½ΡΡ ΠΊΠΎΠΌΠΏΡΡΡΠ΅ΡΠ½ΡΡ ΡΠΎΠΌΠΎΠ³ΡΠ°ΡΠΈΡ (ΠΠ‘ΠΠ’) ΠΎΡΠ³Π°Π½ΠΎΠ² Π³ΡΡΠ΄Π½ΠΎΠΉ ΠΊΠ»Π΅ΡΠΊΠΈ, Π±ΡΠΎΠ½Ρ
ΠΎΠ°Π»ΡΠ²Π΅ΠΎΠ»ΡΡΠ½ΡΠΉ Π»Π°Π²Π°ΠΆ, Π±ΠΈΠΎΠΏΡΠΈΡ Π»Π΅Π³ΠΊΠΈΡ
Ρ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π±ΠΈΠΎΠΏΡΠ°ΡΠΎΠ², Π° ΡΠ°ΠΊΠΆΠ΅ ΠΊΠ°ΡΠ΅ΡΠ΅ΡΠΈΠ·Π°ΡΠΈΡ ΠΏΡΠ°Π²ΡΡ
ΠΎΡΠ΄Π΅Π»ΠΎΠ² ΡΠ΅ΡΠ΄ΡΠ°. ΠΡΡΡΠΈΠΉ ΠΌΠ΅ΡΠΎΠ΄ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΠΠ β ΠΠ‘ΠΠ’, ΡΠ°ΠΊ ΠΊΠ°ΠΊ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ³ΡΠ°ΡΠΈΡ ΠΎΡΠ³Π°Π½ΠΎΠ² Π³ΡΡΠ΄Π½ΠΎΠΉ ΠΊΠ»Π΅ΡΠΊΠΈ ΠΈΠΌΠ΅Π΅Ρ Π½ΠΈΠ·ΠΊΡΡ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ Π½Π° ΡΠ°Π½Π½ΠΈΡ
ΡΡΠ°Π΄ΠΈΡΡ
Π±ΠΎΠ»Π΅Π·Π½ΠΈ.ΠΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΠΠ ΠΏΡΠΎΠ²ΠΎΠ΄ΡΡ Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΡΠΌΠΈ ACR/EULAR (2017), Π²Π΅Π΄ΡΡΡΡ ΡΠΎΠ»Ρ ΠΈΠ³ΡΠ°ΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΡΡΠΏΡΠ΅ΡΡΠΈΠ²Π½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ β ΡΠΈΠΊΠ»ΠΎΡΠΎΡΡΠ°Π½ ΠΈ ΠΌΠΈΠΊΠΎΡΠ΅Π½ΠΎΠ»Π°ΡΠ° ΠΌΠΎΡΠ΅ΡΠΈΠ». Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ ΠΏΡΠΎΡ
ΠΎΠ΄ΡΡ ΠΈΡΠΏΡΡΠ°Π½ΠΈΡ Π°Π½ΡΠΈΡΠΈΠ±ΡΠΎΠ·Π½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ (ΠΏΠΈΡΡΠ΅Π½ΠΈΠ΄ΠΎΠ½, Π½ΠΈΠ½ΡΠ΅Π΄Π°Π½ΠΈΠ±).
Π Π΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ ΠΏΡΠΈ Π²ΠΈΡΡΡΠ½ΡΡ Π³Π΅ΠΏΠ°ΡΠΈΡΠ°Ρ
Autoimmune reactions are of primary importance in the development of extrahepatic manifestations of viral hepatitis, among which there are rheumatic symptoms and syndromes. The incidence of clinically significant extrahepatic manifestations is shown to be relatively low, but they may be in the foreground in the clinical picture of the disease and are noted for severity. It is concluded that due to the high prevalence of hepatitis and the systemic pattern of their chronic forms, patients with extrahepatic manifestations of viral hepatitis may be encountered in the practice of a therapist and a rheumatologist. The onset of the infection caused by hepatitis viruses may be accompanied by articular lesion therefore the rheumatologist may be the first physician such a patient may resort to.ΠΡΡΠΎΠΈΠΌΠΌΡΠ½Π½ΡΠΌ ΡΠ΅Π°ΠΊΡΠΈΡΠΌ ΠΏΡΠΈΠ½Π°Π΄Π»Π΅ΠΆΠΈΡ Π²Π΅Π΄ΡΡΠ°Ρ ΡΠΎΠ»Ρ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ Π²Π½Π΅ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠ½ΡΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ Π²ΠΈΡΡΡΠ½ΡΡ
Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠ², ΡΡΠ΅Π΄ΠΈ ΠΊΠΎΡΠΎΡΡΡ
Π²ΡΡΡΠ΅ΡΠ°ΡΡΡΡ ΠΈ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠΈΠΌΠΏΡΠΎΠΌΡ ΠΈ ΡΠΈΠ½Π΄ΡΠΎΠΌΡ. Π£ΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΡΠ°ΡΡΠΎΡΠ° ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ
Π²Π½Π΅ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠ½ΡΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎ Π½Π΅Π²ΡΡΠΎΠΊΠ°, Π½ΠΎ ΠΎΠ½ΠΈ ΠΌΠΎΠ³ΡΡ Π²ΡΡ
ΠΎΠ΄ΠΈΡΡ Π½Π° ΠΏΠ΅ΡΠ²ΡΠΉ ΠΏΠ»Π°Π½ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½Π΅ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΈ ΠΎΡΠ»ΠΈΡΠ°ΡΡΡΡ ΡΡΠΆΠ΅ΡΡΡΡ. Π‘Π΄Π΅Π»Π°Π½ Π²ΡΠ²ΠΎΠ΄, ΡΡΠΎ Π² ΡΠ²ΡΠ·ΠΈ Ρ Π²ΡΡΠΎΠΊΠΎΠΉ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡΡ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠ² ΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΡΠΌ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΎΠΌ ΠΈΡ
Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΎΡΠΌ Π² ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠ° ΠΈ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³Π° ΠΌΠΎΠ³ΡΡ Π²ΡΡΡΠ΅ΡΠ°ΡΡΡΡ Π±ΠΎΠ»ΡΠ½ΡΠ΅ Ρ Π²Π½Π΅ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠ½ΡΠΌΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡΠΌΠΈ Π²ΠΈΡΡΡΠ½ΡΡ
Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠ². ΠΠ½ΡΠ΅ΠΊΡΠΈΡ, Π²ΡΠ·Π²Π°Π½Π½Π°Ρ Π²ΠΈΡΡΡΠ°ΠΌΠΈ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠ², ΠΌΠΎΠΆΠ΅Ρ Π΄Π΅Π±ΡΡΠΈΡΠΎΠ²Π°ΡΡ Ρ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΡΡΡΡΠ°Π²ΠΎΠ², ΠΏΠΎΡΡΠΎΠΌΡ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ ΠΌΠΎΠΆΠ΅Ρ ΠΎΠΊΠ°Π·Π°ΡΡΡΡ ΠΏΠ΅ΡΠ²ΡΠΌ Π²ΡΠ°ΡΠΎΠΌ, ΠΊ ΠΊΠΎΡΠΎΡΠΎΠΌΡ ΠΎΠ±ΡΠ°ΡΠΈΡΡΡ ΡΠ°ΠΊΠΎΠΉ ΠΏΠ°ΡΠΈΠ΅Π½Ρ
Π‘ΠΌΠ΅ΡΠ°Π½Π½ΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ
Mixed connective tissue disease (MCTD), also known as Sharp's syndrome, is a rare systemic connective tissue disorder that characterized by a combination of some features of systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, polymyositis with the presence of antibodies to soluble nuclear ribonucleoprotein (anti-U1-RNP) in high titers. The most common clinical manifestations of MCTD include Raynaud's phenomenon, hand edema, muscle weakness, arthralgia/arthritis, and esophageal hypotonia. The course of the disease is mostly benign; however, there are severe cases with damage to the lung, kidneys, cardiovascular system and central nervous system. Poor prognosis and the highest mortality rate are associated with pulmonary hypertension. The diagnosis of MCTD is difficult due to the absence of unified diagnostic criteria and lack of specific manifestations at the onset of the disease. Furthermore, there are no generally accepted guidelines for MCTD treatment.The paper considers the modern concepts of MCTD, its current diagnostic criteria, clinical and immunological features, and treatment.Π‘ΠΌΠ΅ΡΠ°Π½Π½ΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ (Π‘ΠΠΠ‘Π’; ΡΠΈΠ½Π΄ΡΠΎΠΌ Π¨Π°ΡΠΏΠ°) β ΡΠ΅Π΄ΠΊΠΎΠ΅ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠ΅Π΅ΡΡ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΡ
ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΠΊΡΠ°ΡΠ½ΠΎΠΉ Π²ΠΎΠ»ΡΠ°Π½ΠΊΠΈ, ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ, ΡΠ΅Π²ΠΌΠ°ΡΠΎΠΈΠ΄Π½ΠΎΠ³ΠΎ Π°ΡΡΡΠΈΡΠ°, ΠΏΠΎΠ»ΠΈΠΌΠΈΠΎΠ·ΠΈΡΠ° Ρ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ Π°Π½ΡΠΈΡΠ΅Π» ΠΊ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΠΌΡ ΡΠ΄Π΅ΡΠ½ΠΎΠΌΡ ΡΠΈΠ±ΠΎΠ½ΡΠΊΠ»Π΅ΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½Ρ (Π°Π½ΡΠΈ-ΠΈ1-Π ΠΠ) Π² Π²ΡΡΠΎΠΊΠΈΡ
ΡΠΈΡΡΠ°Ρ
. ΠΠ½Π°ΠΈ-Π±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΡΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡΠΌ Π‘ΠΠΠ‘Π’ ΠΎΡΠ½ΠΎΡΡΡ ΡΠ΅Π½ΠΎΠΌΠ΅Π½ Π Π΅ΠΉΠ½ΠΎ, ΠΎΡΠ΅ΠΊ ΠΊΠΈΡΡΠ΅ΠΉ, ΠΌΡΡΠ΅ΡΠ½ΡΡ ΡΠ»Π°Π±ΠΎΡΡΡ, Π°ΡΡΡΠ°Π»Π³ΠΈΠΈ/Π°ΡΡΡΠΈΡΡ, Π³ΠΈΠΏΠΎΡΠΎΠ½ΠΈΡ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π°. Π’Π΅ΡΠ΅Π½ΠΈΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ Π΄ΠΎΠ±ΡΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅, ΠΎΠ΄Π½Π°ΠΊΠΎ ΠΈΠΌΠ΅ΡΡΡΡ ΡΠ»ΡΡΠ°ΠΈ ΡΡΠΆΠ΅Π»ΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ Ρ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ Π»Π΅Π³ΠΊΠΈΡ
, ΠΏΠΎΡΠ΅ΠΊ, ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ ΠΈ Π¦ΠΠ‘. ΠΠ»ΠΎΡ
ΠΎΠΉ ΠΏΡΠΎΠ³Π½ΠΎΠ· ΠΈ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ°Ρ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΡ ΡΠ²ΡΠ·Π°Π½Ρ Ρ Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠ΅ΠΉ. ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° Π‘ΠΠΠ‘Π’ Π·Π°ΡΡΡΠ΄Π½Π΅Π½Π° Π² ΡΠ²ΡΠ·ΠΈ Ρ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ ΡΠ½ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π² ΠΈ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ Π² Π΄Π΅Π±ΡΡΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. ΠΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ, Π½Π΅ ΡΡΡΠ΅ΡΡΠ²ΡΠ΅Ρ ΠΎΠ±ΡΠ΅ΠΏΡΠΈΠ½ΡΡΡΡ
ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΉ ΠΏΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π‘ΠΠΠ‘Π’.Π ΡΡΠ°ΡΡΠ΅ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½Ρ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΎ Π‘ΠΠΠ‘Π’: ΠΈΠΌΠ΅ΡΡΠΈΠ΅ΡΡ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ, ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ, Π»Π΅ΡΠ΅Π½ΠΈΠ΅
ΠΠΎΠ·ΠΈΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΠΎ Π°Π½ΡΠΈΡΠ΅Π»Π°ΠΌ ΠΊ ΡΠΈΠ±ΠΎΠ½ΡΠΊΠ»Π΅ΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½Ρ ΠΏΡΠΈ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΡ : ΡΠΎΠΊΡΡ Π½Π° ΡΠΈΡΡΠ΅ΠΌΠ½ΡΡ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΡ
The review deals with the problem of antibody production in scleroderma systematica (SDS), with a focus on antiribonucleoprotein (RNP) antibodies: frequency, structure, and clinical associations. SDS is a progressive polysyndromic disease with characteristic lesion of the skin, locomotor apparatus, viscera (heart, lungs, digestive tract, and kidneys), and common vasospastic disorders as Raynaud's syndrome, the basis for which are the processes of connective tissue disorganization with a predominance of fibrosclerotic changes and vascular pathology as peculiar endarteritis obliterans. The presence of antibodies to different autoantigens is a distinguishing feature of SDS. Among the patients who meet the classification criteria for SDS, there is a subgroup of patients who are not found to have SDS-specific antinuclear antibodies, but have antibodies to soluble nuclear autoantigens, namely, antibodies to RNP. This type of autoantibodies is described in various systemic connective tissue diseases: systemic lupus erythematosus, dermatomyositis, polymyositis, and SDS. The detection rate of anti-RNP antibodies in SDS varies from 5 to 30% in different ethnic groups. In addition, positivity for anti-RNP antibodies is a characteristic feature of mixed connective tissue disease. A more detailed study of anti-U1-RNP antibody-positive patients with SDS, by identifying a new subtype of SDS, comparing, and searching for dissimilarities of anti-U1-RNP antibody carriers from other well-described phenotypes of SDS, is of interest today. This problem is relevant, by taking into account the personalized approach to following up patients, which is actively being elaborated in rheumatology.Β ΠΠ±Π·ΠΎΡ ΠΏΠΎΡΠ²ΡΡΠ΅Π½ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ΅ Π°Π½ΡΠΈΡΠ΅Π»ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ (Π‘Π‘Π), Ρ Π°ΠΊΡΠ΅Π½ΡΠΎΠΌ Π½Π° Π°Π½ΡΠΈΡΠ΅Π»Π° ΠΊ ΡΠΈΠ±ΠΎΠ½ΡΠΊΠ»Π΅ΠΎΠΏΡΠΎΡΠ΅ΠΈΠ½Ρ (Π ΠΠ): ΡΠ°ΡΡΠΎΡΠ΅ Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΠΈ, ΡΡΡΡΠΊΡΡΡΠ΅, ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΡΠΌ. Π‘Π‘Π β ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΡΡΡΠ΅Π΅ ΠΏΠΎΠ»ΠΈΡΠΈΠ½Π΄ΡΠΎΠΌΠ½ΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ Ρ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΡΠΌ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠΆΠΈ, ΠΎΠΏΠΎΡΠ½ΠΎ-Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ Π°ΠΏΠΏΠ°ΡΠ°ΡΠ°, Π²Π½ΡΡΡΠ΅Π½Π½ΠΈΡ
ΠΎΡΠ³Π°Π½ΠΎΠ² (ΡΠ΅ΡΠ΄ΡΠ°, Π»Π΅Π³ΠΊΠΈΡ
, ΠΏΠΈΡΠ΅Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΠΊΡΠ°, ΠΏΠΎΡΠ΅ΠΊ) ΠΈ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΠΌΠΈ Π²Π°Π·ΠΎΡΠΏΠ°ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ ΠΏΠΎ ΡΠΈΠΏΡ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° Π Π΅ΠΉΠ½ΠΎ, Π² ΠΎΡΠ½ΠΎΠ²Π΅ ΠΊΠΎΡΠΎΡΡΡ
Π»Π΅ΠΆΠ°Ρ ΠΏΡΠΎΡΠ΅ΡΡΡ Π΄Π΅Π·ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ Ρ ΠΏΡΠ΅ΠΎΠ±Π»Π°Π΄Π°Π½ΠΈΠ΅ΠΌ ΡΠΈΠ±ΡΠΎΠ·Π½ΠΎ-ΡΠΊΠ»Π΅ΡΠΎΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΠΈ ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΏΠΎ ΡΠΈΠΏΡ ΡΠ²ΠΎΠ΅ΠΎΠ±ΡΠ°Π·Π½ΠΎΠ³ΠΎ ΠΎΠ±Π»ΠΈΡΠ΅ΡΠΈΡΡΡΡΠ΅Π³ΠΎ ΡΠ½Π΄Π°ΡΡΠ΅ΡΠΈΠΈΡΠ°. ΠΠ°Π»ΠΈΡΠΈΠ΅ Π°Π½ΡΠΈΡΠ΅Π» ΠΊ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌ Π°ΡΡΠΎΠ°Π½ΡΠΈΠ³Π΅Π½Π°ΠΌ β Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½Π°Ρ ΡΠ΅ΡΡΠ° Π‘Π‘Π. Π‘ΡΠ΅Π΄ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΠ΄ΠΎΠ²Π»Π΅ΡΠ²ΠΎΡΡΡΡΠΈΡ
ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½ΡΠΌ ΠΊΡΠΈΡΠ΅ΡΠΈΡΠΌ Π‘Π‘Π, ΠΈΠΌΠ΅Π΅ΡΡΡ ΠΏΠΎΠ΄Π³ΡΡΠΏΠΏΠ° Π±ΠΎΠ»ΡΠ½ΡΡ
, Ρ ΠΊΠΎΡΠΎΡΡΡ
Π½Π΅ Π²ΡΡΠ²Π»ΡΡΡΡΡ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π΄Π»Ρ Π‘Π‘Π Π°Π½ΡΠΈΡΠ΄Π΅ΡΠ½ΡΠ΅ Π°Π½ΡΠΈΡΠ΅Π»Π°, Π½ΠΎ ΠΏΡΠΈΡΡΡΡΡΠ²ΡΡΡ Π°Π½ΡΠΈΡΠ΅Π»Π° ΠΊ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΡΠΌ ΡΠ΄Π΅ΡΠ½ΡΠΌ Π°ΡΡΠΎΠ°Π½ΡΠΈΠ³Π΅Π½Π°ΠΌ, Π° ΠΈΠΌΠ΅Π½Π½ΠΎ β Π°Π½ΡΠΈΡΠ΅Π»Π°ΠΌ ΠΊ Π ΠΠ. ΠΠ°Π½Π½ΡΠΉ ΡΠΈΠΏ Π°ΡΡΠΎΠ°Π½ΡΠΈΡΠ΅Π» (Π°ΡΡΠΎΠΠ’) ΠΎΠΏΠΈΡΠ°Π½ ΠΏΡΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΠΈΡΡΠ΅ΠΌΠ½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΡ
ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ: ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΠΊΡΠ°ΡΠ½ΠΎΠΉ Π²ΠΎΠ»ΡΠ°Π½ΠΊΠ΅, Π΄Π΅ΡΠΌΠ°ΡΠΎΠΌΠΈΠΎΠ·ΠΈΡΠ΅ ΠΈ ΠΏΠΎΠ»ΠΈΠΌΠΈΠΎΠ·ΠΈΡΠ΅, Π‘Π‘Π. Π§Π°ΡΡΠΎΡΠ° Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ Π°Π½ΡΠΈΡΠ΅Π» ΠΊ Π ΠΠ ΠΏΡΠΈ Π‘Π‘Π Π²Π°ΡΡΠΈΡΡΠ΅Ρ Π² ΡΠ°Π·Π½ΡΡ
ΡΡΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π³ΡΡΠΏΠΏΠ°Ρ
Π² ΠΏΡΠ΅Π΄Π΅Π»Π°Ρ
5β30%. ΠΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ, ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΠΎ Π°Π½ΡΠΈΡΠ΅Π»Π°ΠΌ ΠΊ Π ΠΠ ΡΠ²Π»ΡΠ΅ΡΡΡ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΠΎΠΉ ΡΠ΅ΡΡΠΎΠΉ ΡΠΌΠ΅ΡΠ°Π½Π½ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ. ΠΠ° ΡΠ΅Π³ΠΎΠ΄Π½ΡΡΠ½ΠΈΠΉ Π΄Π΅Π½Ρ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΠΈΠ½ΡΠ΅ΡΠ΅Ρ Π±ΠΎΠ»Π΅Π΅ Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠ΅ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ
Π‘Π‘Π, ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΡ
ΠΏΠΎ Π°Π½ΡΠΈΡΠ΅Π»Π°ΠΌ ΠΊ U1-Π ΠΠ, Ρ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡΡ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΡ Π½ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠ±ΡΠΈΠΏΠ° Π‘Π‘Π, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΠΈ ΠΏΠΎΠΈΡΠΊΠ° ΠΎΡΠ»ΠΈΡΠΈΠΉ Π½ΠΎΡΠΈΡΠ΅Π»Π΅ΠΉ Π°Π½ΡΠΈΡΠ΅Π» ΠΊ U1-Π ΠΠ ΠΎΡ Π΄ΡΡΠ³ΠΈΡ
Ρ
ΠΎΡΠΎΡΠΎ ΠΎΠΏΠΈΡΠ°Π½Π½ΡΡ
ΡΠ΅Π½ΠΎΡΠΈΠΏΠΎΠ² Π‘Π‘Π. ΠΠ°Π½Π½Π°Ρ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅ΡΡΡ Π°ΠΊΡΡΠ°Π»ΡΠ½ΠΎΠΉ, ΡΡΠΈΡΡΠ²Π°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎ ΡΠ°Π·ΡΠ°Π±Π°ΡΡΠ²Π°Π΅ΠΌΡΠΉ Π² ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΏΠ΅ΡΡΠΎΠ½ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ ΠΊ ΠΊΡΡΠ°ΡΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
.
Π Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ΅ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π°Π½ΡΠΈΠ±ΠΈΠΎΡΠΈΠΊΠΎΠ² Π² ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ
To control infections and infectious complications is one of the most urgent challenges in medicine under present-day conditions. At the same time, rational therapy with anti-infective drugs occupies a highly importance place. In rheumatology, the necessity of using antibiotics is associated with at least two factors, such as eradication of a pathogen trigger (an infectious agent that triggers the immunopathological mechanisms of inflammation) and treatment of comorbid infection. The paper gives information on etiological agents and detailed antimicrobial therapy regimens for the major infections observed in modern rheumatology.Π ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
ΡΡΠ»ΠΎΠ²ΠΈΡΡ
Π±ΠΎΡΡΠ±Π° Ρ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡΠΌΠΈ ΠΈ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΡΠΌΠΈ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡΠΌΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΡΠΎΠ±ΠΎΠΉ ΠΎΠ΄Π½Ρ ΠΈΠ· Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΡ
ΠΏΡΠΎΠ±Π»Π΅ΠΌ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ. ΠΡΠΈ ΡΡΠΎΠΌ Π²Π°ΠΆΠ½ΠΎΠ΅ ΠΌΠ΅ΡΡΠΎ ΠΎΡΠ²ΠΎΠ΄ΠΈΡΡΡ ΡΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π°Π½ΡΠΈΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΡΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ. Π ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π°Π½ΡΠΈΠ±ΠΈΠΎΡΠΈΠΊΠΎΠ² ΡΠ²ΡΠ·Π°Π½Π° ΠΏΠΎ ΠΌΠ΅Π½ΡΡΠ΅ΠΉ ΠΌΠ΅ΡΠ΅ Ρ Π΄Π²ΡΠΌΡ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ: ΡΡΠ°Π΄ΠΈΠΊΠ°ΡΠΈΠ΅ΠΉ Π²ΠΎΠ·Π±ΡΠ΄ΠΈΡΠ΅Π»Ρ-ΡΡΠΈΠ³Π³Π΅ΡΠ° (ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ Π°Π³Π΅Π½ΡΠ°, Π·Π°ΠΏΡΡΠΊΠ°ΡΡΠ΅Π³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΎΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ) ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ. ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΎΠ± ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π°Π³Π΅Π½ΡΠ°Ρ
, ΠΏΠΎΠ΄ΡΠΎΠ±Π½ΡΠ΅ ΡΡ
Π΅ΠΌΡ Π°Π½ΡΠΈΠΌΠΈΠΊΡΠΎΠ±Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΡΠΈ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡΡ
, Π½Π°Π±Π»ΡΠ΄Π°Π΅ΠΌΡΡ
Π² ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ
ASSESSMENT OF THE SENSITIVITY OF NEW CRITERIA FOR SYSTEMIC SCLEROSIS IN RUSSIAN PATIENT POPULATION
Systemic sclerosis (SS) is a progressive connective tissue disease, the prognosis of which largely depends on the time ofΒ adequate therapy initiation. Low sensitivity of the 1980 American College of Rheumatology (ACR) SS classificationΒ criteria for identifying patients with early stage of the disease, and with its limited form in particular, has necessitatedΒ revision of existing SS diagnostic standards and elaboration of more sensitive criteria that allow to establish the diagnosisΒ when the first sign of the disease appear.Objective: to compare the sensitivity of the novel SS criteria of ACR and European League against RheumatismΒ (ACR/EULAR) 2013 and the 1980 ACR criteria in different stages of the disease.Subjects and methods. The investigation enrolled 302 patients who had been diagnosed by experts as having SS andΒ followed up at the V.A. Nasonova Research Institute of Rheumatology in 2007β2013. The patientsβ mean age wasΒ 49Β±13 years (18 to 80 years); male to female ratio β 1:9 (31 and 271), that of patients with diffuse and limited SS βΒ 1:2 (105 and 197); mean duration of the disease from the first non-Raynaudβs syndrome was 8.2Β±7.0 years (6Β months to 36 years). Physical examination, nailfold capillaroscopy, chest radiography or computed tomography,Β echocardiography for the determination of pulmonary artery systolic pressure and SS-specific antibodies evaluationΒ were performed.Results. 273 (90%) patients fulfilled the novel ACR/EULAR 2013 SS criteria. 76 (25%) patients had skin thickeningΒ above the metacarpophalangeal (MPC) joints in both hands; 263 (87%) β finger skin thickening [70 (23%) β fingerΒ swelling, 192 (64%) β thickening of all fingers distal to the MPC joints], 141 (47%) β digital ischemia [79 (26%) β digital pitting scars, 20 (7%) β digital ulcers, 42 (14%) β digital pitting scars and ulcers], 134 (44%) β telangiectasias, 276 (91%) β capillaroscopic changes, 225 (78%) β pulmonary hypertension (PH) or interstitial lung disease (ILD) [15 (5%) β PH 185 (61%) β ILD, 35 (12%) β ILD and PH], 301 (99%) β Raynaudβs phenomenon, and 185 (61%) β SS autoantibodies [138 (46%) β anti-Scl-70 antibodies (a-Scl-70), 42 (14%) β anti-centromere antibodies (ACA), 5 (1.7%) β ACA and a-Scl-70]. 216 (72%) patients fulfilled 1980 ACR SS criteria, and all of them met the novel criteria. With the latter, SS could be additionally diagnosed in 57 more (18%) patients.Conclusion. The 2013 ACR/EULAR SS classification criteria have much higher sensitivity than the 1980 ACR criteria. The sensitivity of the novelΒ criteria remained at the level of 90% in all, including the earliest, stages of the disease while the ACR criteria allowed to confirm diagnosis of SS inΒ only half of patients with a disease duration of less than 1 year
SCLERODERMA SYSTEMATICA WITH INTERSTITIAL LUNG LESION: COMPARATIVE CLINICAL CHARACTERISTICSWITH PATIENTS WITHOUT LUNG LESION
Objective. To compare disease history data and clinical and laboratory parameters in patients with scleroderma systematica (SDS) with high-resolution computed tomography (HRCT)-verified interstitial lung lesion (ILL) versus those without lung involvement. Subjects and methods. An examination was made in 138 patients with SDS who had been consecutively admitted in 2006-2008, female/male ratio, 124 : 14; limited : diffuse : mixed forms, 78 : 40 : 20; mean age, 47Β±13 years; median disease duration, 6 (2.5 11) years. The history data (occupational hazards, smoking, respiratory diseases) and clinical manifestations of SDS and laboratory data were studied. The diagnosis of ILL was established on the basis of chest HRCT. Results. According to HRCT data, the signs of varying ILL were found in 82% of the patients with SDS. The duration of SDS was similar in the patients with and without lung involvement; but the latter were younger at the time of disease onset. There were no significant differences between the groups compared in history data, clinical forms of SDS, the frequency of involvement of visceral organs and systems. Crepitation was heard only in the patients with ILL. The frequency of respiratory manifestations increased with a larger number of the involved lung segments. The prevalence of ILL was found to be positively correlated with age at the onset of SDS (r=0.29;
ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΌΠ°Π³Π½ΠΈΡΠ½ΠΎ-ΡΠ΅Π·ΠΎΠ½Π°Π½ΡΠ½ΠΎΠΉ ΡΠΎΠΌΠΎΠ³ΡΠ°ΡΠΈΠΈ Π² Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΈΠ΄ΠΈΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ ΠΌΠΈΠΎΠΏΠ°ΡΠΈΠΉ
Idiopathic inflammatory myopathies (IIMs) are a group of autoimmune diseases characterized by cross-striated muscle inflammation accompanied by muscle weakness. The rarity of these diseases and a large number of other diseases with similar clinical presentation, along with the absence of simple laboratory tests for confirming the diagnosis of IIMs can cause diagnostic difficulties. The latter may particularly frequently occur in the differentiation of polymyositis from sporadic inclusion body myositis, and late-onset limb-girdle muscular dystrophies. Magnetic resonance imaging of the thigh and leg muscles is of great importance for the differential diagnosis of myopathies, including autoimmune ones.ΠΠ΄ΠΈΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΌΠΈΠΎΠΏΠ°ΡΠΈΠΈ (ΠΠΠ) β Π³ΡΡΠΏΠΏΠ° Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½Π½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Π΄Π»Ρ ΠΊΠΎΡΠΎΡΡΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΠΎ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎΠΏΠ΅ΡΠ΅ΡΠ½ΠΎ-ΠΏΠΎΠ»ΠΎΡΠ°ΡΠΎΠΉ ΠΌΡΡΠΊΡΠ»Π°ΡΡΡΡ Ρ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΠΌ ΠΌΡΡΠ΅ΡΠ½ΠΎΠΉ ΡΠ»Π°Π±ΠΎΡΡΠΈ. Π Π΅Π΄ΠΊΠΎΡΡΡ Π΄Π°Π½Π½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Π½Π°Π»ΠΈΡΠΈΠ΅ Π±ΠΎΠ»ΡΡΠΎΠ³ΠΎ ΡΠΈΡΠ»Π° Π±ΠΎΠ»Π΅Π·Π½Π΅ΠΉ Ρ ΠΏΠΎΡ
ΠΎΠΆΠ΅ΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΠΊΠΎΠΉ ΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΠΏΡΠΎΡΡΡΡ
Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΡΠ΅ΡΡΠΎΠ² Π΄Π»Ρ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½ΠΈΡ Π΄ΠΈΠ°Π³Π½ΠΎΠ·Π° ΠΠΠ ΠΌΠΎΠ³ΡΡ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡΡ ΠΊ ΡΡΡΠ΄Π½ΠΎΡΡΡΠΌ ΠΏΡΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅. ΠΡΠΎΠ±Π΅Π½Π½ΠΎ ΡΠ°ΡΡΠΎ Π²ΠΎΠ·Π½ΠΈΠΊΠ°ΡΡ ΡΠ»ΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΏΡΠΈ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°ΡΠΈΠΈ ΠΏΠΎΠ»ΠΈΠΌΠΈΠΎΠ·ΠΈΡΠ°, ΡΠΏΠΎΡΠ°Π΄ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΌΠΈΠΎΠ·ΠΈΡΠ° Ρ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΡΠΌΠΈ ΠΈ ΠΏΠΎΡΡΠ½ΠΎ-ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΡΡΠ½ΡΡ
ΠΌΡΡΠ΅ΡΠ½ΡΡ
Π΄ΠΈΡΡΡΠΎΡΠΈΠΉ Ρ ΠΏΠΎΠ·Π΄Π½ΠΈΠΌ Π΄Π΅Π±ΡΡΠΎΠΌ. ΠΠ°Π³Π½ΠΈΡΠ½ΠΎ-ΡΠ΅Π·ΠΎΠ½Π°Π½ΡΠ½Π°Ρ ΡΠΎΠΌΠΎΠ³ΡΠ°ΡΠΈΡ ΠΌΡΡΡ Π±Π΅Π΄Π΅Ρ ΠΈ Π³ΠΎΠ»Π΅Π½Π΅ΠΉ ΠΈΠ³ΡΠ°Π΅Ρ Π²Π°ΠΆΠ½ΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π² Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΌΠΈΠΎΠΏΠ°ΡΠΈΠΉ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½Π½ΡΡ
- β¦